Literature DB >> 19040800

Initial experience with silver-impregnated polyurethane ventricular catheter for shunting of cerebrospinal fluid in patients with infected hydrocephalus.

Yusuf Izci1, Halilibrahim Secer, Cemal Akay, Engin Gonul.   

Abstract

OBJECTIVE: Infection is a major complication and risk factor of cerebrospinal fluid (CSF) shunting procedures. Recently, antibiotic-impregnated shunt systems have been developed in an attempt to prevent or reduce the CSF infection. The aim of this study was to determine the efficacy of silver-impregnated polyurethane ventricular catheter for shunting of CSF in patients with infected hydrocephalus.
METHODS: Seven patients who had hydrocephalus with high protein level and positive CSF culture underwent implantation of ventriculoperitoneal shunt with silver-impregnated polyurethane ventricular catheter. All of them experienced shunt failure previously due to infection. The Silverline ventricular catheter, which was connected to the Miethke gravity-assisted valve system and peritoneal catheter, was used in all patients. The mean follow-up period after operation was 14 months. Cerebrospinal fluid samples from the reservoir of the shunts were obtained at the end of the third month after operation in all patients.
RESULTS: The CSF protein level of the patients was reduced significantly, and the CSF culture became negative after shunt placement with silver-impregnated polyurethane ventricular catheters. The mean CSF silver (Ag) level was 0.51 ng/ml [parts per billion (ppb)], and blood Ag level was 3.65 ng/ml (ppb) at the first month after operation. No shunt obstruction or infection was observed in the follow-up period.
CONCLUSION: Silver-impregnated polyurethane ventricular catheters appear to be safe and well tolerated in patients who sustained infected hydrocephalus. Preliminary results suggest a complete improvement of infection. Longer follow-up and large number of patients are needed to more accurately assess the efficacy of these catheters.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19040800     DOI: 10.1179/174313209X380973

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  6 in total

1.  Silver toxicity with the use of silver-impregnated dressing and wound vacuum-assisted closure in an immunocompromised patient.

Authors:  Cabrini A Lariviere; Adam B Goldin; Jeffrey Avansino
Journal:  J Am Col Certif Wound Spec       Date:  2011-05-27

2.  Protective effect of rifampicin and clindamycin impregnated devices against Staphylococcus spp. infection after cerebrospinal fluid diversion procedures.

Authors:  Raquel Gutiérrez-González; Gregorio R Boto; Cristina Fernández-Pérez; Náyade del Prado
Journal:  BMC Neurol       Date:  2010-10-12       Impact factor: 2.474

3.  Management of ventriculo-peritoneal shunts in the paediatric population.

Authors:  David Low; James M Drake; Wan Tew Seow; Wai Hoe Ng
Journal:  Asian J Neurosurg       Date:  2010-01

4.  Controllable degradation kinetics of POSS nanoparticle-integrated poly(ε-caprolactone urea)urethane elastomers for tissue engineering applications.

Authors:  Lara Yildirimer; Asma Buanz; Simon Gaisford; Edward L Malins; C Remzi Becer; Naiem Moiemen; Gary M Reynolds; Alexander M Seifalian
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

5.  The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol.

Authors:  Michael D Jenkinson; Carrol Gamble; John C Hartley; Helen Hickey; Dyfrig Hughes; Michaela Blundell; Michael J Griffiths; Tom Solomon; Conor L Mallucci
Journal:  Trials       Date:  2014-01-03       Impact factor: 2.279

6.  Silver-impregnated, antibiotic-impregnated or non-impregnated ventriculoperitoneal shunts to prevent shunt infection: the BASICS three-arm RCT.

Authors:  Conor L Mallucci; Michael D Jenkinson; Elizabeth J Conroy; John C Hartley; Michaela Brown; Tracy Moitt; Joanne Dalton; Tom Kearns; Michael J Griffiths; Giovanna Culeddu; Tom Solomon; Dyfrig Hughes; Carrol Gamble
Journal:  Health Technol Assess       Date:  2020-03       Impact factor: 4.014

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.